Results 221 to 230 of about 9,892 (240)

Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure

Journal of the American College of Cardiology, 2017
G Michael Felker, Mona Fiuzat, Nanette K Wenger   +2 more
exaly  

Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database

Drug Safety, 2015
Paul B Watkins, James H Lewis, Neil Kaplowitz   +2 more
exaly  

Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload

Journal of the American College of Cardiology, 2017
Ravi Dhingra, Susan J Pressler, Joseph M Massaro   +2 more
exaly  

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial

Nephrology Dialysis Transplantation, 2018
Vicente E Torres, Arlene B Chapman, Olivier Devuyst   +2 more
exaly  

Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease

Kidney International, 2019
Ron T Gansevoort, Arlene B Chapman, Ronald D Perrone   +2 more
exaly  

Tolvaptan

Reactions Weekly, 2013
openaire   +2 more sources

Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: Results from efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) program

American Heart Journal, 2010
Marco Metra
exaly  

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease

Kidney International, 2011
Maria V Irazabal, Vicente E Torres, Holly B Krasa   +2 more
exaly  

Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors

Toxicological Sciences, 2017
William J Brock, Kim L R Brouwer, Rachel J Church   +2 more
exaly  

Rationale and Design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3-4 Study

American Journal of Kidney Diseases, 2011
Vicente E Torres, Olivier Devuyst, Ron T Gansevoort   +2 more
exaly